| Identification | Back Directory | [Name]
Erteberel (LY500307) | [CAS]
533884-09-2 | [Synonyms]
CS-897
SERBA-1
LY500307
Erteberel
Phenchlobenpyrrone
Erteberel (LY500307)
LY500307 (Erteberel)
Erteberel (LY500307) USP/EP/BP
(3aS,4R,9bR)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
(3aS,4R,9bR)-1,2,3,3a,4,9b-Hexahydro-4-(4-hydroxyphenyl)cyclopenta[c][1]benzopyran-8-ol
Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aS,4R,9bR)- | [Molecular Formula]
C18H18O3 | [MDL Number]
MFCD22495234 | [MOL File]
533884-09-2.mol | [Molecular Weight]
282.33 |
| Chemical Properties | Back Directory | [Boiling point ]
485.2±45.0 °C(Predicted) | [density ]
1.268 | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in H2O; ≥14.1 mg/mL in DMSO; ≥48.3 mg/mL in EtOH | [form ]
solid | [pka]
9.79±0.30(Predicted) | [color ]
Off-white to light brown |
| Hazard Information | Back Directory | [Uses]
Erteberel is a highly selective estrogen receptor β (ERβ) agonist. | [Biological Activity]
erteberel (ly500307) is a potent and selective erβ (estrogen receptor beta) agonist (ec50 = 0.66 nm). [1]estrogen receptors are nuclear hormone receptors that act as a ligand-activated transcription factor. it regulates gene expression, cell proliferation and differentiation in target tissues and involved in breast cancer, endometrial cancer and osteoporosis etc. [1]in transcription assay of cotransfected human prostate cancer cell line, erteberel showed potency (ec50 = 0.66 nm), selectivity (32-fold) and full agonist function (>90% relative efficacy) to erβ than to erα. [1]in mouse model, prostate wet weight of cd-1 mice were measured following oral daily doses of erteberel for 7 days. results showed reduction on prostate weight in a dose-dependent manner (0.01 mg/kg – 0.05 mg/kg), and no effect on testes/seminal vesicle weight and androgens testosterone/dihydrotestosterone circulating level. [1] | [in vivo]
Erteberel (5?mg/Kg body weight/day, oral, 28 days) treatment significantly reduces tumor growth and promotes apoptosis of GBM tumors in an orthotopic model[2].
Erteberel (5?mg/Kg body weight/day, oral, 40-50 days) treatment improves the overall survival of tumor-bearing mice in the GL26 syngeneic glioma model[2]. | Animal Model: | Athymic mice (5-7 weeks) inoculated with OVCAR-3 cells[2] | | Dosage: | 5mg/Kg body weight | | Administration: | Oral, daily for 28 days | | Result: | Immunohistochemical analysis reveals that Erteberel treatment significantly reduces the number of proliferation marker Ki-67-positive cells and increases the number of TUNEL-positive apoptotic cells[2]. |
| [IC 50]
ERβ: 1.54 nM (Ki); ERβ: 3.61 nM (EC50) | [storage]
Store at -20°C | [References]
[1] norman bh, dodge ja, richardson ti, borromeo ps, lugar cw, jones sa, chen k, wang y, durst gl, barr rj, montrose-rafizadeh c, osborne he, amos rm, guo s, boodhoo a, krishnan v. benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. j med chem. 2006 oct 19;49(21):6155-7. |
|
|